A World-First Product
3-in-1 Coagulation + Anaesthetic+ Healing
Pharmachal Health Group is collaborating with tier-1 Israeli trauma hospital Rambam Health Care Campus to co-develop a new product for treating burns, wounds, haemophilia, and diabetic ulcers.
The collaboration will combine Pharmachal’s patented mini-emulsion “NDDS” drug delivery technology with a novel peptide drug developed at Rambam that has shown significant potential to speed up wound healing, coagulate bleeding, and encourage the formation of new blood vessels.
Human clinical trials will be led by Professor Nadir Director, Blood Clotting Unit at Rambam, Israel and renowned Australian burns specialist Professor Fiona Wood. Dr Lourdes Santiso of the Paediatric Burns Unit in the Roosevelt Hospital in Guatemala City will also participate in the studies, leveraging her experience treating volcanic burns victims with Pharmachal’ s development products.
Pharmachal sees significant scope to produce a world-first 3-in-1 spray for trauma that alleviates pain, rapidly stops bleeding, and accelerates wound healing and recovery.
In vivo trials of Rambam’s Peptide 16AC on mice have already shown highly-positive results, significantly shortening bleeding time and enhancing wound healing. Mouse trials have already begun using 16AC and NOPAYNE in combination, but as separate formulations.
The particle size of Pharmachal’s NDDS drug delivery technology is an order of magnitude smaller than other emulsions, leading to unique interactions at the cellular level, which could magnify the potential of the Peptide 16AC.
About Rambam Health Care Campus
Rambam Health Care Campus is a 1,100-bed academic governmental hospital serving the over 2.5 million residents of Northern Israel.
Rambam is the tertiary referral centre for 12 district hospitals and provides comprehensive medical services in all medical specialties. Committed to the entire spectrum of patient care, ranging from the best treatments and therapies, to the support of clinical research.